Unknown

Dataset Information

0

Accuracy of the new rapid test for monitoring adalimumab levels.


ABSTRACT: Background:The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8?h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples. Methods:Spiked samples from control donors and 120 serum samples from inflammatory bowel disease (IBD) patients undergoing ADL therapy were quantified using lateral flow Quantum Blue® Adalimumab and, the ELISA formats from Immundiagnostik, R-Biopharm and an in-house assay. Results:The rapid-test assay had intraclass correlation coefficients of 0.590, 0.864 and 0.761 when comparing with the Immundiagnostik, R-Biopharm and in-house assays, respectively. For the five therapeutic windows, the accuracy was high: ADL rapid test compared with the Immundiagnostik (58-88%); R-Biopharm, 68-89%; and in house, 60-88%; and kappa statistics revealed 0.492-0.602, 0.531-0.659 and 0.545-0.682, respectively. Conclusions:The Quantum Blue® Adalimumab assay can replace the commonly used ELISA-based ADL quantification kits and it is a reliable alternative to these methods. This rapid-test assay enables the quantitative determination of ADL serum trough level in only 15?min. The developed assay allows measurement of ADL over a wide range. Hence, it represents a valuable tool for the clinician to assess the ADL trough level.

SUBMITTER: Rocha C 

PROVIDER: S-EPMC6393825 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Accuracy of the new rapid test for monitoring adalimumab levels.

Rocha Cátia C   Afonso Joana J   Lago Paula P   Arroja Bruno B   Vieira Ana I AI   Dias Claudia C CC   Magro Fernando F  

Therapeutic advances in gastroenterology 20190227


<h4>Background</h4>The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three estab  ...[more]

Similar Datasets

| S-EPMC7656121 | biostudies-literature
| S-EPMC8270420 | biostudies-literature
| S-EPMC7404380 | biostudies-literature
| PRJEB45440 | ENA
| S-EPMC7752099 | biostudies-literature
| S-EPMC7753858 | biostudies-literature
| S-EPMC8710016 | biostudies-literature
| S-EPMC5562117 | biostudies-other
| S-EPMC4146703 | biostudies-literature
| S-EPMC5519265 | biostudies-literature